John Miller Email & Phone Number

I founded All is Grace Community Partnership Initiative, a nonprofit dedicated to empowering vulnerable communities in Zambia through education, skills training, and trauma healing. I lead the organization in securing resources, setting strategic goals, and developing sustainable programs that address generational challenges and foster holistic community growth.Key Responsibilities:Strategic Vision and Leadership: Established the mission and long-term vision of All is Grace to support resilience and community development, creating impactful programs in education, vocational training, and trauma healing.Fundraising and Financial Oversight: Drive fundraising efforts to sustain and expand initiatives, including grant applications and donor engagement. Manage budgets to ensure financial health as the organization pursues 501(c)(3) tax-exempt status.Program Development and Management: Oversee the All is Grace Community School and vocational training programs, which provide children with access to quality education and equip adults with skills for economic independence.Community and Stakeholder Engagement: Build partnerships with local leaders, stakeholders, and donors. Stay connected to the Zambian community to align programs with their evolving needs.Compliance and Administration: Handle nonprofit formation, legal compliance, and responsible fund management in both the U.S. and Zambia.Impact Communication: Share All is Grace’s story through digital platforms, presentations, and donor communications to engage and grow our supporter base.All is Grace’s mission is deeply personal, built on a commitment to provide opportunities for learning, healing, and resilience. Through this work, we aim to create a foundation for generational growth and lasting positive change.

Boston, Ma, Us

CHAI is working with manufacturers of drug products to expand the product pipeline of low cost, high quality products. CHAI is also working with high-volume, early-adopter countries to overcome barriers that prevent adoption and scale-up, including regulatory hurdles and limited guidance on quality to build a healthy, competitive global market for these products, while negotiating with manufacturers to lower prices.I work across CHAI teams to develop strategies for overcoming key barriers related to product development, filing, approval, introduction and adoption. I am responsible for translating these strategies into actionable items, and managing relationships with manufacturers, partners, SRAs, NDRAs, Ministries of Health and other key stakeholders.

Owner of independent technical and scientific consultancy with expertise in colloid science, product development and manufacture, instrumentation, and experimental design and data analysis.https://enlightenscientific.com

Brentford, Middlesex, Gb

Brentford, Middlesex, Gb

• Key technical contributor to root cause investigation into major incidences of release testing OOS for key GSK inhaled asset that greatly threatened the ability of the company to meet market demand. Identified signification differences between device components that had not been identified previously. Shared findings and provided recommendations to GSK and external supplier technical teams. Provided clarity of my work and emphasized importance to incorporate some or all of my recommendations into ongoing investigations.• Co-developed and executed protocol to investigate sporadic OOS results for stability samples tested using an automated sample collection platform.• Contributed to the successful development and transfer (to manufacturing organization) of a more robust automated testing platform for an MDI asset. Created experimental design to determine the robustness of the method.• Recommended and led QFD-type process for device component redevelopment team in order to assist team and statisticians create a robust and efficient experimental design. • Contributed to oral suspension technical risk assessment in capacity as expert colloid scientist.

Brentford, Middlesex, Gb

• Global Process Robustness for key company inhaled asset core team member• Developed a robust manual dosing method for an MDI fitted with novel valve• Technical expert for global analytical team• Independent product expert for topical gel materials risk analysis• Product expert for topic gel deep dive diagnostic

Brentford, Middlesex, Gb

• Technical expert support for manufacturer of major GSK inhaled assets• Developed method to measure charge of spray impacting cascade impactor throat and showed choice of device components and formulation have significant effect.• Conceived, built and deployed rotary powder flow analyzer to aid definition of design space for pilot scale blending and dosating. Technique requires ~1g sample as compared to 25g or more for COTS equipment. Cost approx. $5K. Demonstrated that order of premixing can significantly affect blend uniformity. Presented at AIChE General Meeting in 2012.• Departmental Lead, dual combination SAR and PAR intranasal spray• Developed Monte Carlo simulation for particle ripening. Showed that laser diffraction analysis of acicular particles can be deconvoluted for more reliable interpretation.• Developed and conducted scientific workflow stream survey to build detailed database of coverage of skills and expertise required to meet departmental objectives.

Brentford, Middlesex, Gb

• Leadership Team Member, global MDI product development• Leader, ADVAIR HFA MDI PPD team• Leader, Inhaled Delivery Sciences (US)• Lead user of statistical and data mining tools. Champion for use of Design For Manufacture (DFM), PAT/SPA and SixSigma principles.• Independently devised a unique apparatus that allows the surface charge of micronized API in liquid HFA to be measured. Demonstrated correlation between conditioning history of micronized albuterol sulfate and the surface charge in response to changing water content of propellant.

Brentford, Middlesex, Gb

• Core team member of development program for next generation of inhaler platforms o Project Team Leader for novel propellant MDI o Participated in external focus groups• Project Team Leader for novel MDI formulation development program

Brentford, Middlesex, Gb

• Led candidate selection and formulation development for safety assessment for a novel surfactant for HFA MDIs• Led pilot plant manufacturing campaigns for novel metered dose inhaler products

Brentford, Middlesex, Gb

• Led external collaboration and demonstrated PoC of novel aerosol generator used with aqueous suspensions of various micronized drugs• Sourced new instruments for characterizing HFA suspension behavior and spray dynamics. Showed link between suspension aggregation state and dose uniformity.

Holtsville, Ny, Us

Provided technical advice to commercialize the light scattering technique I developed for my doctoral research. The Brookhaven ZetaPALS was the first such commercial instrument available. Three other manufacturers have subsequently developed similar instruments based upon my work.

College Station, Tx, Us

London, England, Gb